Infinity Mining Limited · ASX:IMI
Infinity Mining — Investor Presentation (September 2007)
21 slides from Infinity Mining's investor presentation, September 2007
Slide 1: Future In Health Management 2007 - 2008
Future In Health Management 2007 - 2008 Sep 2007
Slide 2: Disclaimer
Disclaimer Except for historical information, this presentation may contain forward – looking statements that reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market co
Slide 3: Capital Structure
Capital Structure Shares on Issue 1,197 million Top 20 Shareholders 28% – Top 2 shareholders ( Allan Blood & Cardanal P/L ) hold 14.7% Market Capitalisation $70 million Share Price Range (12 months) $0.009 to $0.064 Cash in Bank $3.7 million
Slide 4: Corporate Operational Structure
Corporate Operational Structure Senior Management Tom Bonvino CEO – Director Roman Najdecki – CFO – 25 years experience in senior finance roles in a number of industries, covering manufacturing, distribution, consulting and biotechnology both in the public and private company environments. Previousl
Slide 5: Corporate Operational Structure
Corporate Operational Structure Board Members Allan Blood – Chairman – Substantial project and company development experience in Australia and internationally. Formed Australian Power & Energy Limited in 1998 to develop the $5 billion clean coal, gas to liquids project in Victoria which was subseque
Slide 6: Scientific Advisory Board
Scientific Advisory Board Dr Aaron Ginzburg – Chair & CSO Professor Andrew Tonkin • Consultant cardiologist at the Austin and Repatriation Medical Centre and head of the Cardiovascular Research Unit in the Department of Epidemiology and Preventative Medicine at Monash University. Professor Tonkin is
Slide 7: Our Product
Our Product Exclusive technology identifies and measures risk factors for cardiovascular disease (CVD) Cardiovascular disease affects 1 in 5 Australians and kills 1 person every 10 minutes New ECG technology gives cardiologists fast and reliable tools to diagnose heart conditions. The WHO estimates
Slide 8: Our Strategy 2007/08
Our Strategy 2007/08 Maintain and expand Maintain and expand Complete Enter the consumer retail market our clinic services our workplace research study •Pharmacies business business •Gymnasiums •Weight loss companies Active Active Active October Private health fund International Launch Integration N
Slide 9: Our Intelliheart Model
Our Intelliheart Model Our model is scalable and cost effective based on variable cost structure Intelliheart equipment is portable. All tests performed by IM Medical contract technicians. Our operational model is the same for all the market segments we enter
Slide 10: Our Clinic Business
Our Clinic Business Intelliplan provides preliminary testing as part of a GP management plan. And health assessments for 45-49 and 75+ age groups. Intelliplan provides allied health service to facilitate team care arrangements in-house Intelliheart test is sold as a diagnostic or cardiovascular risk
Slide 11: Our Workplace Business
Our Workplace Business Intelliheart allows employers to help reduce workforce risk profile, providing big health and economic benefits Can be applied to all workers in all industries Revenue ranges from $75 to $275 per assessment The Australasian market place has more than 10 million people in the w
Slide 12: Our Consumer Business
Our Consumer Business Consumer risk assessment test launch before Christmas INSERT POSTER Retail price $250 to $300 Will be sold nationally through hundreds of high-profile pharmacy outlets Platform partner will be included to perform the test Current sales initiatives have already commenced in gymn
Slide 13: Our Business with Private Health Funds
Our Business with Private Health Funds Opportunity provided by legislation allowing rebates for preventative health a perfect “fit” to help funds manage high-risk customers Active discussions with several funds Competition in funds industry will promote innovation in product offerings Direct health
Slide 14: Our Research Study
Our Research Study Monash research began in 2007 and will be completed mid 2008 August announcement reported outstanding findings on as a predictor of heart problems Research confirms merit of and provides further market credibility
Slide 15: Our International Launch
Our International Launch Stage 1 New Zealand/Asia/Middle East Stage 2 Europe Stage 3 United States Our international launch will incorporate and products in a staged strategy across the world market
Slide 16: Integration with / The E-Platform & CPI Index
• Integration with - Improves accuracy of standard 12-lead ECG assessment - Enhances unique IP of Intelliheart system • The E-Platform & CPI Index - Web transmission of ECG waves - Quick patient/data search engine - Real-time ECG remote viewing - ECG storage, sending & retrieval system - Privacy, Se
Slide 17: The Opportunity
– the Opportunity • Rising CVD rates driving growth in ECG and cardiac monitoring products • ECG data management systems the only segment witnessing growth in cardiac monitoring devices market • Rising demand for interconnectivity creating growth opportunities (Frost & Sullivan market overview, Apri
Slide 18: Our Achievements
Our Achievements established in clinical setting Potential confirmed by research First steps towards consumer, workplace, health fund markets Unique technology purchased
Slide 19: Our Revenue 2007-08
Our Revenue 2007-08 REVENUE PROFILE LOCAL MARKET $ PER TEST INTELLIHEART Medical Clinics Complementary Allied Health Pharmacy Range From $50 to $300 Gyms & Weight Loss Private Health Fund Workplace CARDANAL Service & License fee + Storage fee per test + Sending/Retrieving fee per ECG INTERNATIONAL I
Slide 20: Our Potential
Our Potential Cutting edge technology in one of health industry’s biggest markets CVD and other chronic diseases taking increasing share of health spending IM Medical innovations co-incide with initiatives for preventative health by governments and insurers Global opportunity through Intelliheart an
Slide 21: Conclusion
Conclusion Solid foundations laid New revenue streams reduce risk and increase margins potential
Infinity Mining — Investor Presentation (September 2007) on 6ix